Australia’s trusted immunisation experts
02 November 2022 | NewsAt least two thirds of Australians, including children and adolescents, have had COVID-19, two national antibody studies findRead the full article
Hosted in partnership with the Australasian Society for Infectious Diseases Vaccination Special Interest Group and The University of Sydney.
View the video of this webinar to:
Professor Andrew Pollard
Professor of Paediatric Infection and Immunity, Oxford Vaccine Group, University of Oxford
Andrew Pollard is the chief investigator leading the development of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 (COVID-19). He previously chaired the NICE meningitis guidelines development group of the United Kingdom (UK) - the NICE topic expert group developing quality standards for management of meningitis and meningococcal septicaemia. He currently chairs the UK Department of Health and Social Care’s Joint Committee on Vaccination and Immunisation and is a member of WHO’s SAGE. Professor Pollard chaired the European Medicines Agency scientific advisory group on vaccines from 2012 to 2020.
Professor Paul Kelly
Chief Medical Officer, Australian Government Department of Health
Paul Kelly is a public health physician and epidemiologist with more than 30 years’ research experience. Prior to his appointment as CMO, Professor Kelly was the Acting Chief Medical Officer, leading the Government’s health response to the ongoing COVID-19 outbreak.
Professor Kelly first joined the Department in March 2019 as the Chief Medical Adviser, Health Products Regulation Group and became the Deputy Chief Medical Officer in February 2020 following the response to the Summer 2019-2020 bushfires. He has worked around the world in health system development and infectious disease epidemiology. Professor Kelly is the Chair of the Australian Health Protection Principle Committee (AHPPC) and as an official member of National Cabinet, has contributed his extensive public health and epidemiological knowledge and experience to the formulation of various plans and advice relating to COVID-19. This has included the publication of statements and guidelines across a wide range of COVID-19 issues.